Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. (Q54539122)

31 May 2018

title

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. (English)

1 reference

31 May 2018

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Yoshiki Hayashi

1

1 reference

31 May 2018

Hirohisa Nakamae

2

1 reference

31 May 2018

Takako Katayama

3

1 reference

31 May 2018

Takahiko Nakane

4

1 reference

31 May 2018

Hideo Koh

5

1 reference

31 May 2018

Mika Nakamae

6

1 reference

31 May 2018

Asao Hirose

7

1 reference

31 May 2018

Kiyoyuki Hagihara

8

1 reference

31 May 2018

Yoshiki Terada

9

1 reference

31 May 2018

Yoshitaka Nakao

10

1 reference

31 May 2018

Masayuki Hino

11

1 reference

31 May 2018

publication date

20 January 2012

1 reference

31 May 2018

published in

Leukemia & Lymphoma

1 reference

31 May 2018

volume

53

1 reference

31 May 2018

issue

6

1 reference

31 May 2018

page(s)

1084-1089

1 reference

31 May 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

10.3109/10428194.2011.647017

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018